TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06147986: A Phase IIa, Dose-Escalation Followed by Randomized, Open-Label, Parallel-Group Study to Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells as an Add-On Treatment for Acute ST-elevation

Sponsor: Ever Supreme Bio Technology Co., Ltd. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 41 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT06147986 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06147986 Rescue Dossier →